Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.

@article{Watanabe1997ClinicalEW,
  title={Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.},
  author={F D Watanabe and Claudy Mullon and Winston R. Hewitt and Nikolaos Arkadopoulos and E. Kahaku and Susumu Eguchi and Theodore M. Khalili and Walid S. Arnaout and Christopher R. Shackleton and Jacek Rozga and Barry A. Solomon and Achilles A. Demetriou},
  journal={Annals of surgery},
  year={1997},
  volume={225 5},
  pages={
          484-91; discussion 491-4
        }
}
OBJECTIVE The purpose of this study was to develop a bioartificial liver (BAL) to treat patients with severe liver failure until they can be either transplanted or recover spontaneously. SUMMARY BACKGROUND DATA Severe acute liver failure is associated with high mortality. Liver transplantation has emerged as an effective therapy for patients who did not respond to standard management. However, because of the donor organ shortage and urgent need for transplantation, many patients die before… 
Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure
TLDR
This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
Liver Support Therapy: An Overview of the AMC-Bioartificial Liver Research
TLDR
The future of the BAL resides in the development of a human-derived hepatocyte cell line as biocomponent of BAL systems, because xenotransplantation legislation in many European countries prohibits the use of porcine hepatocytes in clinically applied BAL systems.
Bioartificial liver in acute liver failure: Impostor or simply misunderstood?
TLDR
This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
Clinical Application of Bioartificial Liver Support Systems
TLDR
Bioartificial liver therapy for bridging patients with ALF to liver transplantation or liver regeneration is promising, and its clinical value awaits further improvement of BAL devices, replacement of hepatocytes of animal origin by human hepatocytes, and assessment in controlled clinical trials.
Advances in bioartificial liver devices
TLDR
Recent advances in liver biology and bioengineering that have impacted the field are highlighted and important issues include choice of cellular components, stabilization of hepatocyte phenotype, bioreactor design, regulation and safety, and clinical trials.
Bioartificial liver support.
TLDR
The authors review the history of extracorporeal liver support for acute liver failure and discuss their experience with a hollow fiber bioartificial liver support system utilizing porcine hepatocytes in the treatment of patients with acute Liver failure.
Phase I Clinical Trial with the AMC-Bioartificial Liver
TLDR
Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.
Bioartificial liver support devices: historical perspectives
TLDR
The survival of patients excluded from liver transplantation or those with potentially reversible acute hepatitis might be improved with temporary artificial liver support.
In vivo efficacy of a bioartificial liver in improving spontaneous recovery from fulminant hepatic failure: a controlled study in pigs.
TLDR
Bioartificial liver increases survival and allows spontaneous recovery in pigs with fulminant hepatic failure and it is shown that treated animals survived and recovered from liver failure versus 22% controls.
Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation.
TLDR
The HepatAssist 2000 is well tolerated, improves cerebral function, and may be used as a bridge to transplantation for patients with liver failure.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Early clinical experience with a hybrid bioartificial liver.
TLDR
BAL treatment is safe and beneficial and can be successfully used as a 'bridge' to transplantation.
A Bioartificial Liver to Treat Severe Acute Liver Failure
TLDR
The bioartificial liver developed by the authors is safe and serves as an effective “bridge” to liver transplant in some patients and in vivo in experimental animals with liver failure.
Artificial liver support systems
TLDR
In a preliminary clinical study, a porcine hepatocyte-based liver support system is used to treat patients with acute liver failure as well as Patients with acute exacerbation of chronic liver disease, and patients in the first group were successfully bridged to a transplant with excellent survival.
Development of a Hybrid Bioartificial Liver
TLDR
Plasma perfusion through a system consisting of a charcoal column and matrix-attached porcine hepatocytes had significant beneficial effects in animals with liver failure and was well tolerated by a patient with liver Failure.
Review: Artificial liver support systems
TLDR
In a preliminary clinical study, a porcine hepatocyte‐based liver support system is used to treat patients with acute liver failure as well as Patients with acute exacerbation of chronic liver disease, successfully bridged to a transplant with excellent survival.
Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation.
TLDR
It is found that liver transplantation is associated with higher mortality for patients with fulminant hepatic failure than for patientsWith chronic liver disease, however.
Reversal of fulminant hepatic failure using an extracorporeal liver assist device
TLDR
A device consisting of a highly differentiated human liver cell line cultured in a hollow fiber cartridge is capable of supporting dogs with acetaminopheninduced fulminant hepatic failure for a period long enough for their own livers to resume function, allowing recovery of hepatocytes that would otherwise have lysed.
Use of a novel bioartificial liver in a patient with acute liver insufficiency.
TLDR
This preliminary report of the first use of this novel BAL system in conjunction with plasmapheresis appears promising and a clinical study is now in progress to prove its efficacy.
Successful application of extracorporeal liver perfusion: a technology whose time has come.
TLDR
These studies suggest that, 30 yr after initial clinical trials, ECLP can be applied safely without the need for arterial access as a bridge to transplantation and potentially, to evaluate the "usability" of questionable donor organs.
...
1
2
...